Introduction {#sec1-1}
============

Eosinophilic skin diseases are characterised by eosinophil infiltration and/or degranulation in skin lesions, with or without blood eosinophilia. Eosinophils can defend against microbes, to regulate inflammation, cause tissue damage, promote remodelling and fibrosis, and initiate pruritus. Tissue eosinophilia can be caused by cytokine-mediated increased differentiation and survival of eosinophils (extrinsic eosinophilic disorders), and mutation-mediated clonal expansion of eosinophils (intrinsic eosinophilic disorders). Increased generation of interleukin (IL)-5 producing T-lymphocytes is often involved \[[@ref1]\].

Eosinophilic skin diseases are heterogeneous. Pruritus is a common symptom. These disorders can be classified in:

\- allergy-related (allergic drug eruption, urticaria, allergic contact dermatitis, atopic dermatitis),- parasitic infestations and arthropod bites,- infection-related (chronic pulmonary aspergillosis, HIV, Toxocara canis),- autoimmune blistering (bullous pemphigoid, dermatitis herpetiformis), and- those of unknown origin (idiopathic).

The latter group, which is extremely heterogeneous and rare, includes Wells syndrome (eosinophilic cellulitis), granuloma faciale, eosinophilic pustular folliculitis, recurrent cutaneous eosinophilic vasculitis, Job syndrome, angiolymphoid hyperplasia with eosinophilia, and eosinophilic fasciitis \[[@ref2]\]. Here we present a case of Wells syndrome with a remarkable delay of diagnosis.

Case Report {#sec1-2}
===========

A 28-year older man presented with recently developed pruritic and sometimes painful erythema ([Figure 1](#F1){ref-type="fig"}). His medical history was positive for coughing in the evening that started in November 2012. In January 2018, he contacted his GP because of fever. He got a prescription for codeine and oral antibiotic.

![Clinical presentation of Wells syndrome (eosinophilic cellulitis) with large erythematous and brownish macules with slightly elevated borders: abdominal (left); axillary (right)](OAMJMS-7-3002-g001){#F1}

Because of a feeling of pressure and fullness of the paranasal sinuses, he went to an ENT specialist. The allergy tests remained negative, and he got a prescription for 200 mg-cineole capsules.

In April 2018 he experienced a short breath in addition to coughing and greenish sputum. The pulmonologist diagnosed infection-triggered asthma. A corticoid asthma spray improved coughing temporarily.

He presented himself again to the ENT specialist in July 2018 because of persistent coughing and nasal speech. He got a prescription for an oral antibiotic, prednisolone tablets and a corticoid-containing nasal-spray. In August 2018 he suffered an allergic shock after novaminsulfon intake. A respiratory insufficiency was treated in the intensive care unit. Oral prednisolone medication was continued. A computerised tomography (CT) of paranasal sinuses demonstrated a massive polypoid pansinusitis with congestion of the cavities. At this point, the erythematous skin lesions appeared.

On examination, we observed larger erythematous to brownish macules with a slightly elevated border of the armpits, peri- and infra-umbilical, on fingers and thighs. There was no scaling, no blistering ([Figure 1](#F1){ref-type="fig"}).

A diagnostic skin biopsy revealed eosinophilic and neutrophilic infiltrate with dominance of eosinophils of the whole corium with presence of so-called flame figures, i.e. degranulated eosinophils around collagen fibres.

Eosinophilia of the cutis is suggestive of the following three differential diagnoses: Wells syndrome (Eosinophilic cellulitis - EC), Churg-Strauss syndrome (Eosinophilic granulomatosis with polyangiitis - EGPA), and hyper-eosinophilic syndrome (HES).

Imaging: Echocardiography remained unremarkable. Dual X-ray energy of the chest was suggestive of atypical pneumonia treated with oral clindamycin ([Figure 2](#F2){ref-type="fig"}).

![Chest X-ray with atypical pneumonia-like features](OAMJMS-7-3002-g002){#F2}

Body plethysmography excluded obstructive or restrictive ventilation conditions. There was no hint for a diffusion abnormality either.

Abdominal ultrasound demonstrated no pathological findings.

The ENT council confirmed a chronic pansinusitis with an indication for functional endoscopic sinus surgery. Histology of the surgical specimen did not show tissue eosinophilia. After surgery, prednisolone was omitted. The exanthema re-appeared but was less severe. Dyspnea continued.

Laboratory investigation: Eosinophil blood count 23.7 % (normal range: 0.8 -- 7.0) or 2.03 G/L (0.04 -- 0.54), total IgE 416.0 kU/L (\< 100), lymphopenia of 20.0 % (25-45), creatine kinase 3.74 µmol/s \* L (0.00-2.90), total protein 62.4 g/L (66-87), 25-OH-vitamine D 15.5 ng/L (20.0-80.0), C-reactive protein, ANA, c-ANCA, p-ANCA, myeloperoxidase, C3 and C4 complement, antibodies to SSA/Ro, SSB/La, Scl-70, Jo-1, Sm, and RNP70 were normal or negative.

In summary of our findings, we confirmed the diagnosis of Wells syndrome.

The medication at the end of hospital stay consisted of the following medical drugs: Cetirizine 10 mg/d, methyl-prednisolone 8 mg/d, cortisone nasal spray; tiotropium bromide pulmonary spray and salmeterol xinafoate/fluticasone spray, cholecalciferol 20.000 I.U. on day 1 and 15 of each month, and fluocinolone acetonide ointment for a maximum of 4 weeks.

Discussion {#sec1-3}
==========

Our patient underwent an odyssey to the final diagnosis of EC. Eventually, EGPA could be excluded by the normal finding of chest X-ray, body plethysmography, absence of tissue eosinophilia in surgical specimen from pansinusitis surgery, and absence of ANCA in peripheral blood. In skin histology there was no vasculitis, granulomas were missing \[[@ref3]\].

HES has been recently redefined as: (1) Blood eosinophilia of greater than 1500/mm[@ref3] on at least two occasions or evidence of prominent tissue eosinophilia associated with symptoms and marked blood eosinophilia. (2) Exclusion of secondary causes of eosinophilia, such as parasitic or viral infections, allergic diseases, drug-induced or chemical-induced eosinophilia, hypoadrenalism, and neoplasms \[[@ref4]\].

EC or Wells syndrome was described in 1971 by G. C. Wells as recurrent granulomatous dermatitis with eosinophilia \[[@ref5]\]. EC has a sudden onset. During the course of the disease, patients present with recurrent episodes of acute pruritic dermatitis and / or painful edematous swellings or persistent urticarial eruptions. This was a leading symptom in the present patient.

Histopathology is useful in diagnostics. The findings vary with the disease stage, of course. Initially, oedema and a dermal infiltrate of eosinophils are seen. The sub-acute stage, as in our patient, is characterised by fibrinoid flame-figures of mid to deep dermis. Later on, eosinophils tend to disappear and are replaced by histiocytic granulomas. The absence of vasculitis is an important negative sign \[[@ref6]\].

Diagnostic criteria have been proposed by Heelan et al., in 2013 \[[@ref7]\] ([Table 1](#T1){ref-type="table"}).

###### 

Diagnostic criteria for eosinophilic cellulitis (Wells syndrome)

  -------------------------------------------------------------------------------------
  Major criteria (2 of 4 required)
  Any of the previously reported clinical variants
   Plaque-type
   Annular-granuloma-like
   Urticaria-like
   Papulovesicular
   Bullous
   Papulonodular
   Fixed-Drug Eruption-like
  Relapsing, remitting course
  No systemic evidence disease
  Histology: eosinophilic infiltrates, no vasculitis
  Minor (at least 1 required)
   Histology: Flame figures
   Histology: Granulomatous change
   Laboratory: Peripheral eosinophilia not persistent and not greater than \> 1500/μl
   Triggering factor (e.g. drug)
  -------------------------------------------------------------------------------------

The cause of the disease is unknown, but other disorders may be associated with EC such as infections or hematologic disorders or medical drugs. Cases of EC arising in patients receiving biologics are increasingly reported \[[@ref8]\], \[[@ref9]\].

Systemic corticosteroids are usually helpful in EC, but the response may vary about associated pathologies. In our case, the previous corticosteroid treatments were too short, or the dosage was insufficient, leading to recurrences. Standard doses are 1 mg prednisolone per kg body weight. Sometimes higher dosages and repeated course are necessary. Cyclosporin A has been used at doses between 100 and 200 mg/d. Alternatives to systemic corticosteroids are dapsone with a dosage of up to 200 mg/d if there is no glucose-6-phosphate dehydrogenase deficiency, antihistamines (with limited success), colchicine, chloroquine, and azathioprine among others. The combination of prednisolone 50 to 10 mg/d with dapsone 50 mg/d seems to induce a more rapid response. Randomised controlled trials are missing \[[@ref10]\].

New treatment modalities are on the horizon. Case reports on successful treatment of EC with monoclonal anti-IgE antibody omalizumab have been published \[[@ref11]\]. Increased expression of IL-5 has been reported in several cases. Therefore, antibodies directed against IL-5 (e.g. mepolizumab), IL-5-receptor, and Siglec-8 could be a choice. Reduction of tissue eosinophilia can be achieved by dexpramipexole, tyrosine kinase inhibitors, Janus kinase inhibitors, or cytokine inhibitors to IL-13, IL-31, and others \[[@ref12]\].

In conclusion, EC or Wells syndrome is a rare disorder of the spectrum of eosinophilic skin diseases. Diagnosis may be significantly delayed if this rare syndrome is not considered during a chronic relapsing course of variable complaints. Other eosinophilic disorders need to be excluded. Underlying or associated diseases of autoimmune, infectious or malignant nature need careful consideration. Treatment of choice is systemic corticosteroids, but more specific treatment options are on the horizon.
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